lonafarnib has been researched along with Central Nervous System Neoplasm in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, A; Belasco, JB; Blaney, SM; Boyett, JM; Broniscer, A; Frank, E; Geyer, JR; Goldman, S; Gururangan, S; Kieran, MW; Kirschmeier, P; Kun, LE; Onar, A; Packer, RJ; Phillips, P; Pollack, IF; Statkevich, P; Turner, CD; Yver, A; Zhu, Y | 1 |
1 trial(s) available for lonafarnib and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons
Topics: Administration, Oral; Adolescent; Adult; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Piperidines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |